1. Adams DJ, Dewhirst MW, Flowers JL, Gamcsik MP, Colvin OM, Manikumar G, Wani MC, Wall ME (2000) Camptothecin analogs with enhanced antitumor activity at acidic pH. Cancer Chemother Pharmacol 46:263–271
2. Ahmed F, Vyas V, Cornfield A et al (1999) In vitro activation of irinotecan to SN-38 by human liver and intestine. Anticancer Res 19:2067–2071
3. Anguiano A, Nevins JR, Potti A (2008) Towards the individualization of lung cancer therapy. Cancer 113:1760–1767
4. Antony S, Agama KK, Miao ZH, Hollingshead M, Holbeck SL, Wright MH, Varticovski L, Nagarajan M, Morrell A Cushman M, Pommier Y (2006) Bisindenoisoquinoline bis-1,3-{(5,6-dihydro-5,11-diketo-11H-indeno[1,2-c]isoquinoline)-6-propylamino}propane bis(trifluoroacetate) (NSC727357), a DNA intercalator and topoisomerase inhibitor with antitumor activity. Mol Pharmacol 70:1109–1120
5. Bates SE, Medina-Perez WY, Kohlhagen G, Antony S, Nadjem T, Robey RW, Pommier Y (2004) ABCG2 mediates differential resistance to SN-38 (7-ethyl-10-hydroxycamptothecin) and homocamptothecins. J Pharmacol Exp Therap 310:836–842